Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Health & Medicine

Merck, Moderna claim ‘promising’ skin cancer vaccine results in key trial

Both the FDA and the European Medicines Agency have placed the therapy on an expedited review pathway.

We haven't written up this one. Toronto Sun has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at torontosun.com →

More in Health & Medicine

Moderna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial

Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly.

  • Moderna's shares surged 135% to $148.02 after cancer vaccine trial success
  • Intismeran vaccine combined with Merck's Keytruda showed reduced melanoma recurrence
  • Merck's shares rose 11% to $150.14, indicating potential growth for both companies

More from Wednesday 19 August →